newsfilter
← Latest News
Business Wire·

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ:ANGN)